<DOC>
	<DOC>NCT01086293</DOC>
	<brief_summary>The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.</brief_summary>
	<brief_title>Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure, Acute</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 years of age or older Newly prescribed Saxagliptin or an Oral Antidiabetic Drug (OAD) in a class other than Dipeptidyl peptidase IV (DPP4) inhibitors Enrolled in the respective database for at least 180 days prior to the first prescription of new OAD Have at least one diagnostic code for a type 2 diabetesrelated condition Patients identified with a diagnostic code for acute liver failure within the 180day baseline period Patients with DPP4 inhibitor exposure during the baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>